RELATIONSHIP BETWEEN SERUM TRAb AND SOME CLINICAL AND BIOCHEMICAL FEATURES OF GRAVE’S DISEASE IN CHILDREN
Main Article Content
Abstract
Grave’s disease is one of the most common primary hyperthyroidism among patients with thyrotoxicosis. Serum TRAb level, along with clinical and biochemical indicators, contributes to the prognosis of the disease. Objective: Describe the relationship between serum TRAb level and some clinical and biochemical characteristics of Grave’s disease in children. Subjects: 58 children diagnosed with Grave's disease at Vietnam National Children's Hospital from January 2021 to November 2024. Methods: Cross-sectional, retrospective, prospective. Results: The female: male ratio was 41/17 (2.4:1) with a mean age of 9.6 ± 3.1 years. TRAb level at the time of diagnosis, end of induction treatment and maintenance phase were: 22.4 ± 11.3, 15.6 ± 11.4, and 8.8 ± 8.1 U/L, respectively. There was no difference in TRAb level between two groups: under 10 years old and 10-18 years old. TRAb level of the group with grade 2-3 goiter was significantly higher than that in the group with grade 1 goiter at the time of diagnosis, end of induction treatment and maintenance phase (p<0.05). There was an inverse correlation between TRAb index and TSH index in the maintenance phase with a correlation coefficient of 0.47. Conclusion: TRAb level was higher in the group with grade 2-3 goiter compared to the group with grade 1 goiter, TRAb level was inversely correlated with serum TSH level in the maintenance phase. Recommendation: Clinicians need to comprehensively assess the level of goiter, monitor biochemistry including serum FT4, T3, TSH and TRAb levels during the monitoring process to make accurate clinical decisions and effectively treat children with medicine.
Article Details
Keywords
Grave’s disease, TRAb, goiter, TSH, children
References

2. F. Kaguelidou, et al (2008). Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab, vol. 93, no. 10, pp. 3817–3826, doi: 10.1210/jc.2008-0842.


3. J. Léger, I. Oliver, D. Rodrigue, A.-S. Lambert, and R. Coutant (2018). Graves’ disease in children. Ann Endocrinol (Paris), vol. 79, no. 6, pp. 647–655, doi: 10.1016/ j.ando.2018.08.001.


4. M. Q. Meena (2022). Sensitivity and specificity of clinical diagnosis of Graves’ disease and non-Graves’ disorders compared to serum TSH receptor antibodies. Zanco Journal of Medical Sciences (Zanco J Med Sci), vol. 26, no. 1, pp. 13–21, doi: 10.15218/zjms.2022.002.


5. Hùng N. M (2015). Nghiên cứu mối liên quan giữa tự kháng thể TRAb và một số thông số sinh học đến kết quả điều trị bệnh Bệnh Grave’s bằng Methimazole ở trẻ em. Luận án Tiến sĩ y học, Đại học Y Hà Nội.

6. D. Boiro, et al (2017). Hyperthyroidism in children at the University Hospital in Dakar (Senegal). Pan Afr Med J, vol. 28, p. 10, doi: 10.11604/pamj.2017.28.10.13396.


7. C. F. Mooij, et al (2022). 2022 European Thyroid Association Guideline for the management of pediatric Graves’ disease,” Eur Thyroid J, vol. 11, no. 1, p. e210073, doi: 10.1530/ETJ-21-0073.


8. R. S. Bahn Chair, et al (2011). Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid, vol. 21, no. 6, pp. 593–646, doi: 10.1089/thy.2010.0417.

